FDA approves easier-to-clean duodenoscope

New scope will have fewer parts that need to be cleaned


FDA recently granted Pentax approval to market a duodenoscope with fewer parts that need to be cleaned, according to an article on the Advisory Board website.

According to FDA, as many as 350 patients at 41 medical facilities across the globe were infected by or exposed to contaminated gastrointestinal scopes between 2010 and 2015. 

Contaminated scopes had killed at least 35 patients in the United States from 2013 to January 2017.

FDA in 2013 started to collaborate with duodenoscope manufacturers Fujifilm, Olympus, and Pentax to address contamination risks. 

Read the article.

 



December 3, 2019


Topic Area: Infection Control


Recent Posts

Optimizing the Engineering Design of Ambulatory Care Facilities

Designing cost-effective engineering systems is not about minimizing investment but about investing strategically.


Construction Completed on Washington Health Urgent Care Facility in California

The design team maximized the existing footprint to accommodate five exam rooms, a dedicated procedure room and an X-ray room.


OhioHealth Pickerington Methodist Hospital Begins Expansion Project

It includes an expansion of the emergency department (ED) and an additional inpatient unit.


IAQ and Infection Mitigation: Plans Into Actions

To support quality patient care and ensure compliance, managers must stay ahead of environmental and IAQ risks.


Case Study: How NYU Langone Rebuilt for Resilience After Superstorm Sandy

Although the damage was severe, it provided a valuable opportunity for NYU Langone to assess structural vulnerabilities and increase facility resilience.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.